Therapeutic Response
not BRCA2 pathogenic variants status confers therapeutic sensitivity to Niraparib in patients with Ovarian Epithelial Tumor.
Statements
| Source and description |
|---|
not BRCA2 pathogenic variants status confers therapeutic sensitivity to Niraparib in patients with Ovarian Epithelial Tumor.
| Source and description |
|---|